Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 1
1999 1
2001 1
2002 1
2003 1
2004 2
2005 1
2007 4
2008 7
2009 5
2010 22
2011 27
2012 15
2013 6
2014 9
2015 13
2016 16
2017 10
2018 10
2019 15
2020 13
2021 22
2022 17
2023 13
2024 12
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Results by year

Filters applied: . Clear all
Page 1
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL Jr, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Boorjian SA, et al. Among authors: bratslavsky g. Lancet Oncol. 2021 Jan;22(1):107-117. doi: 10.1016/S1470-2045(20)30540-4. Epub 2020 Nov 27. Lancet Oncol. 2021. PMID: 33253641 Free PMC article. Clinical Trial.
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial.
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J Jr, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Narayan VM, et al. Among authors: bratslavsky g. J Urol. 2024 Jul;212(1):74-86. doi: 10.1097/JU.0000000000004020. Epub 2024 May 5. J Urol. 2024. PMID: 38704840 Clinical Trial.
Metastasis development in non-muscle-invasive bladder cancer.
Leyderman M, Chandrasekar T, Grivas P, Li R, Bhat S, Basnet A, Shapiro O, Jacob J, Daneshvar MA, Kord E, Bratslavsky G, Goldberg H. Leyderman M, et al. Among authors: bratslavsky g. Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y. Online ahead of print. Nat Rev Urol. 2024. PMID: 39567681 Review.
Editorial comment.
Singer EA, Srinivasan R, Bratslavsky G. Singer EA, et al. Among authors: bratslavsky g. J Urol. 2011 Jan;185(1):66. doi: 10.1016/j.juro.2010.09.138. Epub 2010 Nov 12. J Urol. 2011. PMID: 21074200 No abstract available.
Editorial comment.
Abouelleil M, Madala A, Bratslavsky G. Abouelleil M, et al. Among authors: bratslavsky g. J Urol. 2012 Nov;188(5):1800. doi: 10.1016/j.juro.2012.07.132. Epub 2012 Sep 19. J Urol. 2012. PMID: 22999685 No abstract available.
Editorial comment.
Shuch B, Pacak K, Linehan WM, Bratslavsky G. Shuch B, et al. Among authors: bratslavsky g. J Urol. 2011 May;185(5):1589-90; author reply 1590. doi: 10.1016/j.juro.2010.12.107. Epub 2011 Mar 21. J Urol. 2011. PMID: 21419442 Free PMC article. No abstract available.
Renal Mass Biopsy: Always, Sometimes, or Never?
Kutikov A, Smaldone MC, Uzzo RG, Haifler M, Bratslavsky G, Leibovich BC. Kutikov A, et al. Among authors: bratslavsky g. Eur Urol. 2016 Sep;70(3):403-6. doi: 10.1016/j.eururo.2016.04.001. Epub 2016 Apr 13. Eur Urol. 2016. PMID: 27085625
A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.
Bex A, Jewett M, Lewis B, Abel EJ, Albiges L, Berg SA, Bratslavsky G, Braun D, Brugarolas J, Choueiri TK, Finelli A, George D, Haas NB, Hakimi AA, Hammers H, Hirsch M, Jonasch E, Kapur P, Linehan WM, Master V, McGregor B, McKay RR, Mehra R, Pal S, Poteat S, Powles TB, Rossi SH, Shapiro DD, Signoretti S, Singer EA, Stravin C, Tannir N, Vaishampayan U, Xu W, Stewart GD. Bex A, et al. Among authors: bratslavsky g. Eur Urol. 2025 Apr;87(4):385-389. doi: 10.1016/j.eururo.2025.01.007. Epub 2025 Jan 23. Eur Urol. 2025. PMID: 39855942
Targeting Hsp90 in urothelial carcinoma.
Chehab M, Caza T, Skotnicki K, Landas S, Bratslavsky G, Mollapour M, Bourboulia D. Chehab M, et al. Among authors: bratslavsky g. Oncotarget. 2015 Apr 20;6(11):8454-73. doi: 10.18632/oncotarget.3502. Oncotarget. 2015. PMID: 25909217 Free PMC article. Review.
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. Leary JB, et al. Among authors: bratslavsky g. Target Oncol. 2024 May;19(3):447-458. doi: 10.1007/s11523-024-01056-x. Epub 2024 Apr 3. Target Oncol. 2024. PMID: 38570422
215 results